Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
NCT06899217 · View on ClinicalTrials.gov ↗
Study Summary
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with idiopathic gastroparesis compared to a placebo * To evaluate the safety of CIN-102 when given to patients with idiopathic gastroparesis compared to a placebo Participants will go through the following schedule: * Pre-screening (1 visit) * Screening \& Lead-In (1-2 visits) * Will complete a Gastric Emptying Breath Test (GEBT) * Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation. * Lead-In Period (1 visit) * 12-week treatment period (7 visits) * Study drug taken twice daily by mouth * Will complete daily diaries and other PROs as described in protocol * 1 week follow-up (1 visit) Researchers will compare the effects of the following treatments: * 15 mg CIN-102, taken orally BID for 12 weeks * 10 mg CIN-102, taken orally BID for 12 weeks * Placebo for CIN-102, taken orally BID for 12 weeks
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CIN-102 Dose 15mg
- DRUG CIN-102 Dose 10mg
Study Locations (20)
California
- Hope Clinical Research LLC — Canoga Park
- Erick H. Alayo Medical Corporation — Chula Vista
- Flourish Research - Los Angeles (Covina) — Covina
- Gastro Care Institute — Lancaster
- Downtown L.A. Research Center, Inc. — Los Angeles
- Acclaim Clinical Research — San Diego
- Focus Clinical Research - West Hills — West Hills
Alabama
- Gastro Health - Birmingham — Birmingham
- G & L Research, LLC — Foley
- The Center for Clinical Trials — Saraland
Colorado
- University of Colorado Anschutz — Aurora
- Rocky Mountain Gastroenterology (RMG) — Lakewood
- Paradigm Research - Wheatridge — Wheat Ridge
Florida
- American Family Research Group — Cape Coral
- USA and International Research Inc. — Doral
- Unique Clinical Trials — Doral
Arkansas
- Applied Research Center of Arkansas, Inc — Little Rock
- Preferred Research Partners, Inc. — Little Rock
Arizona
- Del Sol Research Management, LLC — Tucson
Connecticut
- Connecticut Clinical Research Institute, LLC — Bristol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2025-01-29 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06899217
The ClinicalTrials.gov registry entry for NCT06899217 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 416 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CinDome Pharma, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Idiopathic Gastroparesis appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06899217 reports 20 study locations spanning 7 distinct geographic areas — top geographies include California, Alabama, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06899217 about?
NCT06899217 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.". The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastrop...
What is the current status of trial NCT06899217?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 416 participants. The study started on 2025-01-29. Estimated completion is 2026-05-01.
What conditions does trial NCT06899217 study?
This clinical trial studies the following conditions: Idiopathic Gastroparesis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06899217?
The interventions under investigation include: Placebo (DRUG), CIN-102 Dose 15mg (DRUG), CIN-102 Dose 10mg (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06899217?
This trial is sponsored by CinDome Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06899217 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.